Compare AEG & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AEG | DVA |
|---|---|---|
| Founded | 1983 | 1994 |
| Country | Netherlands | United States |
| Employees | 15304 | N/A |
| Industry | Life Insurance | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 14.9B |
| IPO Year | N/A | 2003 |
| Metric | AEG | DVA |
|---|---|---|
| Price | $9.00 | $236.32 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $156.75 |
| AVG Volume (30 Days) | ★ 5.0M | 701.3K |
| Earning Date | 02-09-2023 | 05-05-2026 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.87 |
| Revenue | N/A | ★ $13,643,069,000.00 |
| Revenue This Year | N/A | $3.85 |
| Revenue Next Year | N/A | $3.07 |
| P/E Ratio | ★ $7.91 | $81.55 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $6.75 | $101.00 |
| 52 Week High | $9.10 | $239.64 |
| Indicator | AEG | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 65.25 | 73.72 |
| Support Level | $8.34 | $145.58 |
| Resistance Level | N/A | $239.64 |
| Average True Range (ATR) | 0.11 | 6.61 |
| MACD | 0.03 | -0.47 |
| Stochastic Oscillator | 87.51 | 88.44 |
Aegon is a life insurance and long-term savings business listed in the Netherlands. It was listed on the Amsterdam Stock Exchange in the 1980s and now has mature operations in the United States, the United Kingdom, and four growth markets of Brazil, China, Portugal, and Spain. In recent years, Aegon has been moving through an extensive transformation program during which management has sought to divest noncore operations and improve the risk profile of the business. Financial assets are the parts of the company that are now being run off. Aegon is looking to cycle out of capital-consumptive and volatile earnings products and recycle capital into capital-light and more predictable strategic businesses.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.